Jay Horrow

13.0k total citations · 2 hit papers
72 papers, 8.7k citations indexed

About

Jay Horrow is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Jay Horrow has authored 72 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Cardiology and Cardiovascular Medicine, 32 papers in Surgery and 11 papers in Internal Medicine. Recurrent topics in Jay Horrow's work include Antiplatelet Therapy and Cardiovascular Diseases (28 papers), Atrial Fibrillation Management and Outcomes (14 papers) and Lipoproteins and Cardiovascular Health (11 papers). Jay Horrow is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (28 papers), Atrial Fibrillation Management and Outcomes (14 papers) and Lipoproteins and Cardiovascular Health (11 papers). Jay Horrow collaborates with scholars based in United States, Sweden and United Kingdom. Jay Horrow's co-authors include Stefan James, Robert F. Storey, Lars Wallentin, Richard C. Becker, Steen Husted, Philippe Gabríel Steg, Kenneth W. Mahaffey, Christopher P. Cannon, Robert A. Harrington and Hugo A. Katus and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jay Horrow

70 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

2009 4.6k citations Lars Wallentin, Richard C. Becker et al. New England Journal of Medicine profile →
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

2010 582 citations Lars Wallentin, Stefan James et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Horrow United States	27	7.7k	3.6k	2.3k	559	467	72	8.7k
Steven R. Steinhubl United States	40	6.9k 0.9×	3.6k 1.0×	2.0k 0.9×	551 1.0×	409 0.9×	105	8.0k
Shmuel Gottlieb Israel	32	7.5k 1.0×	3.0k 0.8×	1.2k 0.5×	445 0.8×	1.1k 2.4×	134	8.6k
Christopher P. Cannon United States	39	11.2k 1.5×	5.3k 1.5×	3.0k 1.3×	703 1.3×	1.3k 2.8×	109	12.4k
Kevin P. Bliden United States	45	8.0k 1.0×	4.2k 1.2×	2.8k 1.2×	1.2k 2.1×	208 0.4×	195	9.5k
Jurriën M. ten Berg Netherlands	55	11.9k 1.6×	5.1k 1.4×	2.7k 1.2×	746 1.3×	1.2k 2.6×	416	13.7k
Victor L. Serebruany United States	24	4.3k 0.6×	1.9k 0.5×	1.2k 0.5×	226 0.4×	343 0.7×	150	5.3k
Michelle L. O’Donoghue United States	43	4.2k 0.6×	3.4k 0.9×	553 0.2×	953 1.7×	511 1.1×	116	6.9k
Jean‐Philippe Collet France	36	3.9k 0.5×	2.2k 0.6×	987 0.4×	717 1.3×	368 0.8×	124	5.1k
John F. Paolini United States	32	8.1k 1.0×	1.3k 0.4×	3.8k 1.7×	627 1.1×	400 0.9×	90	10.5k
Nicolas von Beckerath Germany	35	4.5k 0.6×	2.9k 0.8×	1.0k 0.4×	611 1.1×	575 1.2×	78	6.0k

Countries citing papers authored by Jay Horrow

Since Specialization

Citations

This map shows the geographic impact of Jay Horrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Horrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Horrow more than expected).

Fields of papers citing papers by Jay Horrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Horrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Horrow. The network helps show where Jay Horrow may publish in the future.

Co-authorship network of co-authors of Jay Horrow

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Horrow. A scholar is included among the top collaborators of Jay Horrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Horrow. Jay Horrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gibson, C. Michael, Maria Cecilia Bahit, Roxana Mehran, et al.. (2025). Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). American Heart Journal. 285. 21–28. 4 indexed citations

Horrow, Jay, et al.. (2021). Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial. BMC Anesthesiology. 21(1). 62–62. 14 indexed citations

Raval, Amit D., Sohan Deshpande, S Rabar, et al.. (2020). Does deep neuromuscular blockade during laparoscopy procedures change patient, surgical, and healthcare resource outcomes? A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 15(4). e0231452–e0231452. 28 indexed citations

Cohen, Micah, et al.. (2018). Added value of MRI to X-ray in guiding the extent of surgical resection in diabetic forefoot osteomyelitis: a review of pathologically proven, surgically treated cases. Skeletal Radiology. 48(3). 405–411. 13 indexed citations

Husted, Steen, Stefan James, Richard G. Bach, et al.. (2014). The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal. 35(23). 1541–1550. 58 indexed citations

Kunadian, Vijay, Stefan James, Daniel Wojdyla, et al.. (2013). Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC: Cardiovascular Interventions. 6(7). 671–683. 30 indexed citations

Wallentin, Lars, Stefan James, Evangelos Giannitsis, et al.. (2012). Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 126. 3 indexed citations

Wallentin, Lars, Stefan James, Robert F. Storey, et al.. (2012). GREATER EFFICACY OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME IS NOT DRIVEN BY OUTCOMES IN POOR METABOLIZERS OF CLOPIDOGREL. Journal of the American College of Cardiology. 59(13). E500–E500. 1 indexed citations

Cannon, Christopher P., Robert F. Storey, Steen Husted, et al.. (2012). RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL. Journal of the American College of Cardiology. 59(13). E629–E629.

10.

James, Stefan, Robert F. Storey, Cheryl Bushnell, et al.. (2011). Abstract 15029: Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes and History of Stroke or Transient Ischemic Accident: Results from the Platelet Inhibition and Patient Outcomes Trial. Circulation. 124. 1 indexed citations

11.

Patel, Manesh R., Richard C. Becker, Daniel Wojdyla, et al.. (2011). Abstract 14299: Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial. Circulation. 124. 1 indexed citations

12.

Mahaffey, Kenneth W., Daniel Wojdyla, Kevin Carroll, et al.. (2011). Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 124(5). 544–554. 287 indexed citations

13.

Husted, Steen, Stefan James, Richard C. Becker, et al.. (2011). TICAGRELOR VERSUS CLOPIDOGREL IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROMES: A SUBANALYSIS FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology. 57(14). E1099–E1099. 4 indexed citations

14.

Janzon, Magnus, Martin Henriksson, Ole Hauch, et al.. (2010). Abstract 17295: Health Economics in the PLATelet inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns. Circulation. 122. 4 indexed citations

15.

James, Stefan, Andrzej Budaj, Philip E. Aylward, et al.. (2010). Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation. 122(11). 1056–1067. 259 indexed citations

16.

Held, Claes, Nils Åsenblad, Jean Pierre Bassand, et al.. (2010). Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology. 57(6). 672–684. 331 indexed citations

17.

Wallentin, Lars, Richard C. Becker, Andrzej Budaj, et al.. (2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 361(11). 1045–1057. 4626 indexed citations breakdown →

18.

Baruch, Lawrence, Brian F. Gage, Jay Horrow, et al.. (2007). Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?. Stroke. 38(9). 2459–2463. 57 indexed citations

19.

Horrow, Jay, et al.. (2007). Heart rate variability changes during pregnancy: an observational study. International Journal of Obstetric Anesthesia. 16(2). 106–109. 23 indexed citations

20.

Weiss, Matthew J., Daniel Nyhan, Zhihao Peng, et al.. (1989). Association of Protamine IgE and IgG Antibodies with Life-Threatening Reactions to Intravenous Protamine. Survey of Anesthesiology. 5(2). 280–281. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact